T. Jake Liang, M.D.


Chief, Liver Diseases Branch

Liver Diseases Branch
LIVER DISEASES BRANCH
NIDDK, National Institutes of Health
Building 10 , Room 9B16
10 Center Dr.
Bethesda, MD 20814
Tel: 301-496-1721
Fax: 301-402-0491
Email: jakel@mail.nih.gov

T. Jake Liang, M.D.

Education / Previous Training and Experience:
B.A., Harvard College, 1980
M.D., Harvard Medical School, 1984


Research Statement:

Infection with hepatitis B and C viruses affects more than 10 percent of the world population and is the most common etiology of chronic liver disease and hepatocellular carcinoma, which is the fourth leading cause of death from cancer in the world. Current therapies for both viruses are less than optimal. While an effective vaccine for HBV is available, the prospect for a HCV vaccine remains elusive. Given the magnitude and severity of both viral infections as a global public health problem, it is imperative to develop and implement effective prophylactic vaccines and better therapeutic regimens. To achieve this goal, we must understand at the molecular, cellular and genetic levels the viral life cycle, viral mechanisms for productive and persistent infection, virus-host interactions, and host immune responses. The thematic effort of my laboratory focuses on these topics.

While many gaps in our knowledge of HCV exist, great strides have been made in characterizing the virus and functions of viral genes as well as in unraveling the replication pathway and immunologic mechanisms of liver injury. HCV, like many other viruses, exploit host cellular machinery for productive infection. However, unlike other RNA viruses, HCV has a high propensity to cause persistent infection despite an active host immune response. Thus, it possesses unique mechanisms to counteract the various host defenses. HCV gene products have been shown to interact with many host factors and to induce cellular alterations vital for viral replication, persistence and pathogenesis. Earlier progress in HCV research has been hampered by a lack of robust infectious and replicating cell culture systems and convenient small animal models. The development of in vitro systems including infectious cell cultures affords the opportunity to fully characterize viral replication and virus-cell interactions. SCID/uPA mice transplanted with human hepatocytes susceptible to HCV infection and transgenic mouse models have been useful as small animal models. We have taken three approaches to study HCV infection and pathogenesis.

  1. To understand the mechanisms of action of interferon, ribavirin, and the new class of direct-acting antivirals in HCV therapy, and to explore the biological basis of treatment non-response in order to improve current treatment regimen.

  2. To apply molecular, biochemical and functional genomic tools to identify and characterize structural and functional interactions among the virus, viral gene products and the host.

  3. To generate novel reagents and tools for developing and evaluating vaccines and antivirals by building and improving on currently available model systems.

For HBV, the replication and virus-host interactions have been studied in great detail and many of the pathways have been elucidated. The availability of culture systems and small animal models has greatly facilitated the elucidation of fundamental knowledge of the virus and the evaluation of vaccine and therapeutic candidates. While the various virologic functions in replication are well-known, the roles of interacting cellular factors remain largely undefined. In addition, the viral and host functions for productive and persistent infection in vivo are poorly understood. Among the viral gene products, the accessory proteins HBeAg and HBX are not essential for replication in vitro but appear to be important for viral infection in vivo. The HBX has multifarious effects and appears to function through several pathways including signal transduction, transcriptional activation/DNA repair, and/or cellular proteolysis. These mechanisms may not be mutually exclusive and can be concurrently operative in contributing to the pleiotropic effect of HBX. Despite the uncertainty about the mechanism of HBX functions, it has been generally accepted that this gene product is required for the establishment of HBV infection in vivo. We have been focusing on understanding the functions of HBX and developing therapeutic strategy targeting at this important viral function. We are also applying our overall approach in functional genomics described above for HCV to studying HBV-host interactions.



Selected Publications:

Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Holm H, et al. Genome-wide association study identifies loci influencing plasma levels of liver enzymes. Nature Genetics 2011;43:1131-1138. [Full Text/Abstract]

Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B. Early changes in natural killer cell function indicate virological response to interferon-based therapy of hepatitis C. Gastroenterology 2011; 141: 1231-1239. [Full Text/Abstract]

Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011; 54:1135-1148. [Full Text/Abstract]

Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi, Y, Krawczynski K, Liang, TJ, Wakita T, Kato T. In vivo adaptation of hepatitis C virus for efficient virus production and evasion of apoptosis. Hepatology 2011; 54: 425-433. [Full Text/Abstract]

Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. Host response to translocated microbial products predicts clinical outcome in human HBV and HCV infections. Gastroenterology 2011; 141:1220-1230. [Full Text/Abstract]

Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, Alter HJ, Herrine SK, Liang TJ, Hoofnagle JH, Heller T. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011; 33: 559-65. [Full Text/Abstract]

Feld J, Spurva AA, El-Diwany R, Rotman Y, Koh C, Cherepanov V, Heller T, Ghany MG, Park Y, Hoofnagle JH, Liang TJ. S-adenosyl methionine combination with perginterferon and ribavirin improves early viral kinetics and interferon stimulated gene induction in previous genotype 1 hepatitis C nonresponders. Gastroenterology 2011; 140:830-839. [Full Text/Abstract]

Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of HCV RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011; 140: 676-685. [Full Text/Abstract]

Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32-41. [Full Text/Abstract]

Zhang Z, Sun E, OU J-H J, Liang TJ. Inhibition of cellular proteasome activities enhances HBX-dependent hepatitis B virus replication in vivo. J Virol 2010; 84: 9326-9331. [Full Text/Abstract]

Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ and the NASH-CRN. The association of genetic variability in PNPL3 with histological severity of non-alcoholic fatty liver disease. Hepatology 2010; 52: 894-903. [Full Text/Abstract]

De Mochel NSR, Seronello S, Ito C, Zheng JX, Wang SH, Liang TJ, Lambeth JRD, Choi J. Hepatocyte NAD(P)H oxidase as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology 2010; 52: 47-59. [Full Text/Abstract]

Feld JJ, Lutchman GA, Heller T, Pfeiffer J, Hara K, Rivera M, Ko M, Koh C, Rotman Y, Ghany MG, Haynes-Williams V, Neumann AU, Liang TJ*, Hoofnagle JH. Ribavirin improves early responses to peginterferon through enhancing interferon signaling. Gastroenterology 2010; 139: 154-162. [Full Text/Abstract]

Rotman Y, Borg B, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, and Hoofnagle JH. Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther 2010; 31: 1018-1027. [Full Text/Abstract]

He X-S, Nanda S, Ji X, Calderon-Rodriquez G, Greenberg HB, Liang TJ. Differential transcriptional responses to IFN-a and IFN-g in primary human hepatocytes. J Interferon & Cytokine Res 2010; 30: 25-34. [Full Text/Abstract]

Zhang Y, Zhang B, Liang TJ. A novel function of CD81 in HCV life cycle involving viral replication. J Virol 2010; 84: 3396-3407. [Full Text/Abstract]

Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51: 201-209. [Full Text/Abstract]

Ahlenstiel G, Titerence RH, Koh C, Feld J, Rotman Y, Ghany M, Hoofnagle JH, Liang TJ, Heller T, Rehermann B. Natural killer cell function is polarized towards cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010; 13 [Full Text/Abstract]

Li Q, Brass AL, Ng A, Xavier R, Liang TJ*, Elledge SJ. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Submitted to Proc Natl Acad Sci USA 2009; 106: 16410-16415. [Full Text/Abstract]

Yee LJ, Im K, Borg B, Yang H, Liang TJ and Virahep-C Study. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immunity 2009; 10: 365-372. [Full Text/Abstract]

Matsumura T, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau J-M, Cosset F-L, Chayama K, Vaillant A, Liang TJ. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009; 137: 673-681. [Full Text/Abstract]

Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009; 83: 7366-7374. [Full Text/Abstract]

Nanda S, Havert M, Calderon GM, Thomson M, Jacobson C, Kastner D, Liang TJ. Hepatic transcriptome analysis of hepatitis C virus infection of chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE 2008;3: e3442. [Full Text/Abstract]

Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokhar F, Lutchman G, Kleiner DE, Young NS, Childs R, Barrett AJ, Liang TJ, Hoofnagle JH, Heller T. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009; 7: 1130-1137. [Full Text/Abstract]

Yee LJ, Im KA. Wahed AS, Bugawan T, Li J, Rhodes SL, Erlich H, Rosen HR, Liang TJ, Yang H for the Virahep-C Study. Polymorphism in the human MHC and the early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Chemother 2009; 53: 615-621. [Full Text/Abstract]

Liang TJ. Hepatitis B: the Virus and Disease. Hepatology 2009; 49: S13-S21. [Full Text/Abstract]

Loomba R, Lutchman G, Kleiner D, Ricks M, Feld J, Borg BB, Modi A, Premkumar A, Sumner AE, Liang TJ, Hoofnagle JH. A pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182. [Full Text/Abstract]

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41. [Full Text/Abstract]

Barth H, Robinet E, Liang TJ, Baumert TF. Mouse models for study of HCV infection and virus-host interactions. J Hepatology 2008; 49:134-142. [Full Text/Abstract]

Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Placebo in nonalcoholic steatohepatitis: insights into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol 2008; 11: 1243-1248. [Full Text/Abstract]

Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Pre-emptive lamivudine therapy reduces the risk of chemotherapy-induced hepatitis B virus related morbidity and mortality in hepatitis B surface antigen positive cancer patients. Annals of Internal Med 2008; 148:519-528. [Full Text/Abstract]

Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendation for a standardized approach. Gastroenterology 2008; 134: 405-415. [Full Text/Abstract]

Su X, Yee LJ, Im KA, Rhodes SL, Tang Y, Tong X, Howell C, Ramcharran D, Rosen HR, Taylor MW, Liang TJ, Yang H. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatology 2008; 49: 184-191. [Full Text/Abstract]

Rhodes SL, Erlich H, Im KA, Wang J, Liu J, Bugawan T, Jeffers L, Tong X, Su X, Rosen HR, Yee LJ, Liang TJ, Yang H. Association between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immunity 2008; 9: 328-333. [Full Text/Abstract]

Loomba R, Hwang S-J, O’Donnell CJ, Ellison RC, Vasan RS, D’Agostino RB, Liang TJ, Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham Heart Study. Gastroenterology 2008; 2008: 953-959. [Full Text/Abstract]

Barth H, Schnober EK, Neumann-Haefelin C, Thimme R, Diepolder HM, Liang TJ, Blum HE, Baumert TF. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 2008; 82: 3466-3479. [Full Text/Abstract]

Modi AA, Liang TJ Hepatitis C: a clinical review. Oral Dis(14): 10-4, 2008. [Full Text/Abstract]

Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology(47): 306-20, 2008. [Full Text/Abstract]

Huang Y, Yang H, Borg BB, Su X, Rhodes SL, Yang K, Tong X, Tang G, Howell CD, Rosen HR, Thio CL, Thomas DL, Alter HJ, Sapp RK, Liang TJ A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A(104): 985-90, 2007. [Full Text/Abstract]

Yu X, Qiao M, Atanasov I, Hu Z, Kato T, Liang TJ, Zhou ZH Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology(367): 126-34, 2007. [Full Text/Abstract]

Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy K, Liang TJ Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology(132): 733-44, 2007. [Full Text/Abstract]

Ghany M, Liang TJ Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology(132): 1574-85, 2007. [Full Text/Abstract]

Hussain N, Feld JJ, Kleiner DE, Hoofnagle JH, Garcia-Eulate R, Ahlawat S, Koziel DE, Anderson V, Hilligoss D, Choyke P, Gallin JI, Liang TJ, Malech HL, Holland SM, Heller T Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology(45): 675-83, 2007. [Full Text/Abstract]

Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology(46): 1548-63, 2007. [Full Text/Abstract]

Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A(104): 8427-32, 2007. [Full Text/Abstract]

Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS Management of hepatitis B: summary of a clinical research workshop. Hepatology(45): 1056-75, 2007. [Full Text/Abstract]

Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, Ghany MG Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology(132): 1757-66, 2007. [Full Text/Abstract]

Yee LJ, Tang YM, Kleiner DE, Wang D, Im K, Wahed A, Tong X, Rhodes S, Su X, Whelan RM, Fontana RJ, Ghany MG, Borg B, Liang TJ, Yang H

13. Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, Wakita T, Liang TJ Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol(81): 4405-11, 2007. [Full Text/Abstract]

Liang TJ Shortened therapy for hepatitis C virus genotype 2 or 3--is less more? N Engl J Med(357): 176-8, 2007. [Full Text/Abstract]

Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology(46): 424-9, 2007. [Full Text/Abstract]

Hu Z, Zhang Z, Kim JW, Huang Y, Liang TJ Altered proteolysis and global gene expression in hepatitis B virus X transgenic mouse liver. J Virol (80): 1405-13, 2006. [Full Text/Abstract]

Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, Liang TJ, Hoofnagle JH Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol(4): 1048-52, 2006. [Full Text/Abstract]

Feld JJ, Liang TJ Hepatitis C -- identifying patients with progressive liver injury. Hepatology(43): S194-206, 2006. [Full Text/Abstract]

Barth H, Liang TJ, Baumert TF Hepatitis C virus entry: molecular biology and clinical implications. Hepatology(44): 527-35, 2006. [Full Text/Abstract]

Loomba R, Liang TJ Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther(11): 1-15, 2006. [Full Text/Abstract]

Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, Liang TJ, Hoofnagle JH, Ghany MG Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology(43): 780-7, 2006. [Full Text/Abstract]

Liang TJ Supporting the NIH before it is too late. Hepatology(44): 1-2, 2006. [Full Text/Abstract]

Nanda SK, Herion D, Liang TJ The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology(130): 794-809, 2006. [Full Text/Abstract]

Heller T, Saito S, Auerbach J, Williams T, Moreen TR, Jazwinski A, Cruz B, Jeurkar N, Sapp R, Luo G, Liang TJ An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (102): 2579-83, 2005. [Full Text/Abstract]

Feld JJ, Liang TJ HCV persistence: cure is still a four letter word. Hepatology (41): 23-5, 2005. [Full Text/Abstract]

Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, Grullich C, Nassal M, Liang TJ, Blum HE, von Weizsacker F Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology (41): 247-56, 2005. [Full Text/Abstract]

Kim WH, Hong F, Jaruga B, Zhang ZS, Fan SJ, Liang TJ, Gao B Hepatitis B virus X protein sensitizes primary mouse hepatocytes to ethanol- and TNF-alpha-induced apoptosis by a caspase-3-dependent mechanism. Cell Mol Immunol (2): 40-8, 2005. [Full Text/Abstract]

Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (11): 791-6, 2005. [Full Text/Abstract]

Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (79): 13963-73, 2005. [Full Text/Abstract]

Balasubramanian A, Munshi N, Koziel MJ, Hu Z, Liang TJ, Groopman JE, Ganju RK Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. J Gen Virol (86): 3291-301, 2005. [Full Text/Abstract]

Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccala G, Depla E, Liang TJ, Blum HE, Baumert TF Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood (105): 3605-14, 2005. [Full Text/Abstract]

Promrat K Lutchman G Uwaifo GI Freedman RJ Soza A Heller T Doo E Ghany M Premkumar A Park Y Liang TJ Yanovski JA Kleiner DE Hoofnagle JH A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (39): 188-96, 2004. [Full Text/Abstract]

Rahman F Heller T Sobao Y Mizukoshi E Nascimbeni M Alter H Herrine S Hoofnagle J Liang TJ Rehermann B Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (40): 87-97, 2004. [Full Text/Abstract]

Cai Z Liang TJ Luo G Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cell. J Virol (78): 3633-43, 2004. [Full Text/Abstract]

Keck ZY Sung VM Perkins S Rowe J Paul S Liang TJ Lai MM Foung SK Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol (78): 7257-63, 2004. [Full Text/Abstract]

Jeong SH Qiao M Nascimbeni M Hu Z Rehermann B Murthy K Liang TJ Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol (78): 6995-7003, 2004. [Full Text/Abstract]

Qiao M, Ashok M, Bernard KA, Palacios G, Zhou ZH, Lipkin WI, Liang TJ Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis (190): 2104-8, 2004. [Full Text/Abstract]

Zhang Z Protzer U Hu Z Jacob J Liang TJ Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J Virol (78): 4566-72, 2004. [Full Text/Abstract]

Steinmann D, Barth H, Gissler B, Schurmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G, Patel AH, Inchauspe G, Liang TJ, Blum HE, Baumert TF Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (78): 9030-40, 2004. [Full Text/Abstract]

Radaeva S Jaruga B Kim WH Heller T Liang TJ Gao B Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochem J (379): 199-208, 2004. [Full Text/Abstract]

Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (9): 679-93, 2004. [Full Text/Abstract]

Liang TJ, Heller T Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology (127): S62-71, 2004. [Full Text/Abstract]

Promrat K McDermott DH Gonzalez CM Kleiner DE Koziol DE Lessie M Merrell M Soza A Heller T Ghany M Park Y Alter HJ Hoofnagle JH Murphy PM Liang TJ Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (124): 352-60, 2003. [Full Text/Abstract]

Promrat K Liang TJ Chemokine systems and hepatitis C virus infection: is truth in the genes of the beholders? Hepatology (38): 1359-62, 2003. [Full Text/Abstract]

Milich D Liang TJ Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology (38): 1075-86, 2003. [Full Text/Abstract]

Qiao M Murata K Davis AR Jeong SH Liang TJ Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology (37): 52-9, 2003. [Full Text/Abstract]

Murata K Lechmann M Qiao M Gunji T Alter HJ Liang TJ Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A (100): 6753-8, 2003. [Full Text/Abstract]

Hoofnagle JH Ghany MG Kleiner DE Doo E Heller T Promrat K Ong J Khokhar F Soza A Herion D Park Y Everhart JE Liang TJ Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (38): 66-74, 2003. [Full Text/Abstract]

Ghany MG Kleiner DE Alter H Doo E Khokar F Promrat K Herion D Park Y Liang TJ Hoofnagle JH Progression of fibrosis in chronic hepatitis C. Gastroenterology (124): 97-104, 2003. [Full Text/Abstract]

Thomson M Nascimbeni M Havert MB Major M Gonzales S Alter H Feinstone SM Murthy KK Rehermann B Liang TJ The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol (77): 862-70, 2003. [Full Text/Abstract]






Update My page

Page last updated: February 16, 2012

General inquiries may be addressed to:
Office of Communications & Public Liaison
NIDDK, NIH
Bldg 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
USA
301.496.3583

The National Institutes of Health   Department of Health and Human Services   USA.gov is the U.S. government's official web portal to all federal, state, and local government web resources and services.  This website is certified by Health On the Net Foundation. Click to verify.